Analyse court terme - SHIRE PLC : Le retracement de 62% est atteint, il cause le repli.
La tendance est toujours haussière, son niveau d'invalidation est sous 3 525,00 p. L'objectif est à 4 388,00 p.Arguments :
- La résistance a été dépassée, mais elle est réintégrée. Les prix peuvent baisser.
- Le retracement de 62% est atteint, il cause le repli.
- Les prix dépassent la moyenne mobile, c'est un signal de force.
- Le gap haussier ouvert en sortie de figure annonce la hausse.
Shire is a holding company. Through its subsidiaries, Co. operates as a biotechnology company focused on serving people with rare diseases and other conditions. Co.'s portfolio covers seven therapeutic areas: Immunology, Hematology, Neuroscience, Internal Medicine (IM), Genetic Diseases, Oncology, and Ophthalmics. Some of Co.'s marketed products include GAMMAGARD, HYQVIA and CINRYZE for Immunology, ADVATE/ADYNOVATE, VONVENDI and FEIBA for Hematology, VYVANSE and ADDERALL XR for Neuroscience, LIALDA/MEZAVANT and PENTASA for IM, ELAPRASE and REPLAGAL for Genetic Diseases, ONCASPAR and ONYVIDE for Oncology and XIIDRA for Ophthalmics.
DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.